CD1C and neoplasm: To directly test the ability of CD1c+CD14+ cells to induce anti-tumor CD8 T cell responses, we performed 4-day co-cultures of flow cytometry-sorted CD1c+CD14+ and CD1c+CD14− cells with autologous CD8 T cells transfected with a T cell receptor (TCR) that recognizes the NY-ESO1p157-165 peptide, derived from tumor antigen New York esophageal squamous cell carcinoma 1 (NY-ESO1), presented in HLA-A∗02:01 (Figure 2C).